A review of treatment options for patients with newly diagnosed acute myeloid leukemia and differences between patients who are fit vs unfit for chemotherapy.
Tamibarotene in Newly Diagnosed Acute Myeloid Leukemia (AML)
Dr Daniel Pollyea comments on biomarker testing in acute myeloid leukemia and the potential role for RARA testing.
Daniel Pollyea, MD, MS, reviews the initial results from the biomarker-directed phase 2 tamibarotene trial that were presented at ASH 2020.
Dr Daniel Pollyea discusses the role of venetoclax plus an HMA agent in patients with AML and talks about some possible mechanisms of resistance to the venetoclax-HMA combination.
Daniel Pollyea, MD, MS, reviews the ongoing SELECT-AML-1 trial and comments on novel therapies and biomarkers in patients with newly diagnosed unfit AML.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5